Metabolic Dysfunction-Associated Steatohepatitis (MASH): Seven-Market Drug Forecast and Market Analysis - Update

Table of Contents

Table of Contents

List of Tables

List of Figures

1 MASH: Executive Summary

• 1.1 Summary of Changes
• 1.2 The MASH market will grow significantly during the forecast period, reaching sales of $20.2 billion in 2032
• 1.3 R&D strategies in MASH include unique MOAs, staging of MASH, and exploring combination therapies
• 1.4 More approved treatment options and use of non-invasive diagnosis options remain the greatest unmet needs in the MASH space
• 1.5 Opportunity for non-invasive tests to be at the forefront of MASH patient diagnosis and management
• 1.6 Innovative pipeline products demonstrating high levels of effectiveness and tolerable safety profiles will acquire large market share
• 1.7 What do physicians think?

2 Introduction

• 2.1 Catalyst
• 2.2 Related reports
• 2.3 Upcoming reports

3 Disease Overview

• 3.1 Etiology and pathophysiology
  • 3.1.1 Etiology
  • 3.1.2 Pathophysiology
• 3.2 Classification or staging systems

4 Epidemiology

• 4.1 Disease background
• 4.2 Risk factors and comorbidities
• 4.3 Global and historical trends
• 4.4 Forecast methodology
  • 4.4.1 Sources
  • 4.4.2 Forecast assumptions and methods
  • 4.4.3 Forecast assumptions and methods: diagnosed prevalent cases of MASLD
  • 4.4.4 Forecast assumptions and methods: total prevalent cases of MASLD
  • 4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of MASH
  • 4.4.6 Forecast assumptions and methods: diagnosed prevalent cases of MASH by fibrosis stage
  • 4.4.7 Forecast assumptions and methods: diagnosed prevalent cases of MASH with compensated and decompensated cirrhosis
• 4.5 Epidemiological forecast for MASH (2022-32)
  • 4.5.1 Diagnosed prevalent cases of MASH
  • 4.5.2 Age-specific diagnosed prevalent cases of MASH
  • 4.5.3 Sex-specific diagnosed prevalent cases of MASH
  • 4.5.4 Diagnosed prevalent cases of MASH by fibrosis stage
  • 4.5.5 Diagnosed prevalent cases of cirrhosis attributable to MASH
• 4.6 Discussion
  • 4.6.1 Epidemiological forecast insight
  • 4.6.2 Obesity omission
  • 4.6.3 COVID-19 impact
  • 4.6.4 Limitations of the analysis
  • 4.6.5 Strengths of the analysis

5 Disease Management

• 5.1 Diagnosis overview
• 5.2 Treatment
  • 5.2.1 Rezdiffra
  • 5.2.2 Vitamin E
  • 5.2.3 Pioglitazone
• 5.3 Guidelines
• 5.4 Key opinion leader insights on disease management
  • 5.4.1 Guidelines on diagnosis and non-invasive testing
  • 5.4.2 Guidelines on treatment

6 Competitive Assessment

• 6.1 Overview

7 Unmet Needs and Opportunity Assessment

• 7.1 Overview
• 7.2 Need for more approved therapies
• 7.3 Cost-efficient non-invasive tests for patient monitoring and potential diagnosis
• 7.4 Understanding of MASH pathophysiology
• 7.5 Cost-effective novel therapies and improved access

8 R&D Strategies

• 8.1 Overview
  • 8.1.1 Combination therapies to target multiple pathways
  • 8.1.2 Differential targeting of early- and late-stage NASH
  • 8.1.3 Use of AI to facilitate drug discovery and to standardize histologic scoring
• 8.2 Clinical trials design
  • 8.2.1 Patient selection
  • 8.2.2 Clinically meaningful endpoints and study period
  • 8.2.3 Employing biomarkers to measure therapeutic response

9 Pipeline Assessment

• 9.1 Overview
• 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

• 10.1 Overview
• 10.2 Competitive assessment

11 Current and Future Players

• 11.1 Overview
• 11.2 Deal-making trends

12 Market Outlook

• 12.1 Global markets
  • 12.1.1 Forecast
  • 12.1.2 Drivers and barriers - global issues
• 12.2 US
  • 12.2.1 Forecast
  • 12.2.2 Key events
  • 12.2.3 Drivers and barriers
• 12.3 5EU
  • 12.3.1 Forecast
  • 12.3.2 Key events
  • 12.3.3 Drivers and barriers
• 12.4 Japan
  • 12.4.1 Forecast
  • 12.4.2 Key events
  • 12.4.3 Drivers and barriers

13 Appendix

• 13.1 Bibliography
• 13.2 Abbreviations
• 13.3 Methodology
  • 13.3.1 Forecasting methodology
• 13.4 Primary research - KOLs and payers interviewed for this report
  • 13.4.1 KOLs
  • 13.4.2 Payer(s)
• 13.5 Primary research - prescriber survey
• 13.6 About the authors
  • 13.6.1 Analyst
  • 13.6.2 Managing Analyst
  • 13.6.3 Therapy Area Director
  • 13.6.4 Epidemiologist
  • 13.6.5 Managing Epidemiologist
  • 13.6.6 Vice President of Disease Intelligence and Epidemiology
  • 13.6.7 Global Head of Pharma Research, Analysis, and Competitive Intelligence
• About GlobalData
• Contact Us